| (USD) | Sep 2023 | Q/Q |
|---|---|---|
| Revenue | 3.3MM | +13% |
| Gross Profit | 107K | -87% |
| Cost Of Revenue | 3.2MM | +50% |
| Operating Income | -14.7MM | +16% |
| Operating Expenses | 14.8MM | - |
| Net Income | 910K | -103% |
| R&D | 7MM | +20% |
| G&A | 7.8MM | +3% |
| Interest Expense | - | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Accelerate Diagnostics, Inc. (NASDAQ:AXDX) Q4 2023 Earnings Call Transcript March 28, 2024 Accelerate Diagnostics, Inc. misses on earnings expectations. Reported EPS is $-0.89 EPS, expectations were $-0.62. Accelerate Diagnostics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, and […]
Q4 2023 Accelerate Diagnostics Inc Earnings Call
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -43.55% and 20.34%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and year ended December 31, 2023.
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that management will host a conference call on Thursday, March 28, 2024, at 4:30 p.m. Eastern Time to review 2023 fourth quarter and full year results.
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) (the "Company") today announced the pricing of an underwritten public offering consisting of 6,860,659 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, and for certain investors in lieu thereof, pre-funded units, each consisting of one pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock. The public offering price for each unit is $1.50 a
Accelerate Diagnostics, Inc. (NASDAQ: AXDX) (the "Company") today announced the launch of a proposed underwritten public offering of 4,500,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, or for certain investors, pre-funded units in lieu thereof, with each pre-funded unit consisting of one-pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock, pursuant to a registration stateme
Accelerate Diagnostics, Inc. (Nasdaq: AXDX) (Accelerate), an in vitro diagnostics company dedicated to providing services that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections, today announced certain preliminary, unaudited results for the quarter and year ended December 31, 2023.
Accelerate Diagnostics' (AXDX) Arc system eliminates the need for overnight culture incubation, drastically reducing the wait time for identification results.
Bruker (BRKR) and Accelerate Diagnostics are set to work together to bring rapid, automated microbial identification directly from positive blood culture samples.